Effects of Anserine/Carnosine Supplementation on Mild Cognitive Impairment with APOE4.

Masuoka N, Yoshimine C, Hori M, Tanaka M, Asada T, Abe K, Hisatsune T

Nutrients17 Jul 2019Cited by 52 (Europe PMC)

PMID31319510PMCIDPMC6683059DOI10.3390/nu11071626PepBankPUB-31319510

Summary

BackgroundOral supplementation of anserine/carnosine helps preserve cognitive functions in healthy older adults. Mild cognitive impairment (MCI) is a transition between cognitive-normal and dementia. Therefore, it needs to investigate whether anserine/carnosine supplementation (ACS) has effects on subjects with MCI.MethodsA randomized, double-blind, placebo-controlled 12-week trial was performed. Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1). Evaluation of cognitive change was conducted utilizing a psychometric test battery.ResultsThe score improvement in the global Clinical Dementia Rating (gloCDR) was superior in the active group than placebo (p = 0.023). No beneficial effect in the active group was detected in the other psychometric tests including the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale, and the Alzheimer's Disease Assessment Scale (ADAS). When APOE4 positive (APOE4 (+)) or negative (APOE4 (-)) subjects were separately analyzed, beneficial change in the APOE4 (+) subjects was observed in MMSE (p = 0.025) as well as in gloCDR (p = 0.026).ConclusionsThe present study might suggest that protective effects against cognitive decline in APOE4 (+) MCI subjects exist.

CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study6

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone6

In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking L-carnosine.

01HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome
In people with mild cognitive impairment, anserine/carnosine improved global Clinical Dementia Rating scores more than placebo.
In plain wordsIn people with mild cognitive impairment, anserine/carnosine improved global Clinical Dementia Rating scores more than placebo.
Peptide
L-carnosine
Outcome
Direction not reportedGlobal Clinical Dementia Rating
Study
n = 54
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
The score improvement in the global Clinical Dementia Rating (gloCDR) was superior in the active group than placebo (p = 0.023).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled 12-week trial was performed.
Summary · context
Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1).
In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.
Show in the study text Report a problemFND-3131951001
02HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome
In people with mild cognitive impairment, anserine/carnosine showed no beneficial MMSE effect versus placebo.
In plain wordsIn people with mild cognitive impairment, anserine/carnosine showed no beneficial MMSE effect versus placebo.
Peptide
L-carnosine
Outcome
No significant changeMini-Mental State Examination
Study
n = 54
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
No beneficial effect in the active group was detected in the other psychometric tests including the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale, and the Alzheimer's Disease Assessment Scale (ADAS).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled 12-week trial was performed.
Summary · context
Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1).
In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.
Show in the study text Report a problemFND-3131951002
03HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome
In people with mild cognitive impairment, anserine/carnosine showed no beneficial Wechsler Memory Scale effect versus placebo.
In plain wordsIn people with mild cognitive impairment, anserine/carnosine showed no beneficial Wechsler Memory Scale effect versus placebo.
Peptide
L-carnosine
Outcome
No significant changeWechsler Memory Scale
Study
n = 54
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
No beneficial effect in the active group was detected in the other psychometric tests including the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale, and the Alzheimer's Disease Assessment Scale (ADAS).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled 12-week trial was performed.
Summary · context
Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1).
In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.
Show in the study text Report a problemFND-3131951003
04HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome
In people with mild cognitive impairment, anserine/carnosine showed no beneficial ADAS effect versus placebo.
In plain wordsIn people with mild cognitive impairment, anserine/carnosine showed no beneficial ADAS effect versus placebo.
Peptide
L-carnosine
Outcome
No significant changeAlzheimer's Disease Assessment Scale
Study
n = 54
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
No beneficial effect in the active group was detected in the other psychometric tests including the Mini-Mental State Examination (MMSE), the Wechsler Memory Scale, and the Alzheimer's Disease Assessment Scale (ADAS).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled 12-week trial was performed.
Summary · context
Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1).
In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.
Show in the study text Report a problemFND-3131951004
05HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome
In APOE4-positive people with mild cognitive impairment, anserine/carnosine produced beneficial MMSE change versus placebo.
In plain wordsIn APOE4-positive people with mild cognitive impairment, anserine/carnosine improved MMSE results versus placebo.
Peptide
L-carnosine
Outcome
Direction not reportedMMSE in APOE4-positive subgroup
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
When APOE4 positive (APOE4 (+)) or negative (APOE4 (-)) subjects were separately analyzed, beneficial change in the APOE4 (+) subjects was observed in MMSE (p = 0.025) as well as in gloCDR (p = 0.026).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled 12-week trial was performed.
Summary · context
Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1).
In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.
Show in the study text Report a problemFND-3131951005
06HumanNot a test of L-carnosine aloneRandomized controlled trialEfficacy outcome
In APOE4-positive people with mild cognitive impairment, anserine/carnosine produced beneficial global CDR change versus placebo.
In plain wordsIn APOE4-positive people with mild cognitive impairment, anserine/carnosine improved global CDR results versus placebo.
Peptide
L-carnosine
Outcome
Direction not reportedGlobal CDR in APOE4-positive subgroup
Study
n: not reported in source
Comparator
Placebo
Outcome group
Cognition and memory · Nervous system and cognition
Source sentences
Summary
When APOE4 positive (APOE4 (+)) or negative (APOE4 (-)) subjects were separately analyzed, beneficial change in the APOE4 (+) subjects was observed in MMSE (p = 0.025) as well as in gloCDR (p = 0.026).
2 context sentences(design, population, supporting numbers)
Summary · context
A randomized, double-blind, placebo-controlled 12-week trial was performed.
Summary · context
Fifty-four subjects with MCI were randomized to an active group ingesting 750 mg of anserine and 250 mg of carnosine per day or a placebo (1:1).
In this study, L-carnosine was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking L-carnosine.
Show in the study text Report a problemFND-3131951006

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
27 Oct 2026, 18:20 UTC
Study results updated
Version 1
27 Oct 2026, 16:32 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.